Answers are grounded in this paper and cite their sources.
We read with concern the article by Spelman et al., 'Efficacy and safety analysis: 24-month outcomes from a prospective cohort of 106 fields treated with widefield radiation therapy for extensive skin field cancerization, with or without keratinocyte cancers'.1 This report does not demonstrate efficacy or safety of wide field radiation therapy (WFRT) for extensive skin field cancerization (ESFC). ESFC is a new concept, with current definitions capturing solar damage only, to actinic keratoses with or without occasional low risk skin malignancies, to patients whose burden of skin malignancy is so high that lesion directed treatment cannot keep pace. The authors contend that WFRT for ESFC has benefits such as improved quality of life and reduction in new lesions in treated areas. Without a control group meaningful measurement of these parameters is impossible. As the study emanates from a region with the highest rate of solar related issues in the world, a matched control group is readily available. Meaningful detail on the severity of the treated ESFC, the size or grade of invasive cancers, whether they were biopsy-proven, the reasons for 'surgical caution', the reported comorbidities, the nature of prior treatments and why these were deemed 'exhausted' or inappropriate is lacking. Almost two thirds of their patients had nothing more serious than actinic keratosis or intraepidermal carcinoma. It is unclear why these patients were prescribed radiation therapy rather than one of the many alternate, lower risk, less morbid and cheaper treatments. How is the reader to judge the relative benefit of WFRT in the absence of a comparator group? All except one author are financially linked to the treating organisation. Coupled with the absence of a control group rendering blinded assessment of outcome impossible, the risk of real or perceived bias in the reporting of benefits and complications is high. Within the data presented there are concerning features that we have raised previously.2 At only 2-year follow-up new lesions, including invasive malignancy, were already developing in 10% of the treatment fields. Two of 10 treated BCCs recurred. Management of invasive malignancies with radiation fields is rendered more difficult. Fibrosis and vascular compromise impair healing and graft take. If any of these malignancies had features such as perineural invasion, the use of post operative radiation would be relatively contraindicated. Late toxicity with radiation (fibrosis, poikiloderma, ulceration and second malignancy) is well documented and the follow-up period here is too short to document the incidence and severity of this complication. Idiosyncratic induction of multiple squamous cell carcinomas within volumetric modulated arc therapy fields has been recently reported.3, 4 These risks would cause most clinicians to exercise extreme caution for using this modality for mere solar damage or low risk malignancy where treatments with a higher therapeutic index could be employed. While VMAT is a technical advance in the delivery of RT for skin cancer, enabling larger volumes to be treated regardless of contour, and improved capacity to limit dose to nearby important normal structures, the process of widening RT fields to include areas of actinic keratosis or of treating actinic keratoses alone remains unsupported by any high-level evidence of efficacy or safety. Selected patients with a high burden of invasive and in situ disease who are exhausting efforts to treat invasive lesions may benefit from wide field RT, but the uncertain outcome, and the long-term effects, including the potential to undermine treatment of subsequent cancers should be considered. The use should not be expanded without reliable assessment of efficacy and safety with well-designed, controlled trials, with blinded outcome assessment. actinic keratoses, basal cell carcinoma, radiation therapy, skin cancer, squamous cell carcinoma Tiffany Daly and Jim Muir wrote the manuscript, and Michael Veness assisted with editing. The authors have no funding to report. The authors declare no conflict of interest. Ethical Approval: not applicable.
No takes yet. Share an insight, caveat, or question.
Daly et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: